中文产业新闻评分64Chinese source
君赛生物 TIL 疗法 GC101 拟纳入 CDE 优先审评，治疗含 PD-1 抗体失败的转移性黑色素瘤
君赛生物冲刺！或将成为国内首个
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
君赛生物冲刺！或将成为国内首个
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.